每周适应性放疗对比标准调强放疗改善头颈癌患者唾液功能:一项3期随机临床试验
这项在法国11个中心开展的3期随机临床试验纳入132例接受放化疗的III-IVB期口咽鳞癌患者,随机分组接受标准调强放疗(不重新计划)或适应性放疗(每周系统重新计划),主要终点为刺激唾液流率评估的口干频率。12个月时两组刺激唾液流率无显著差异(适应性放疗组630 mg/min vs 标准组584 mg/min,P=.64),仅腮腺排泄功能在适应性放疗组改善(48% vs 41%,P=.02),两组2年总生存率均为76.9%。结论为适应性放疗未显示出较标准调强放疗降低口干症的获益。
要点
- 12个月刺激唾液流率适应性放疗组630 mg/min vs 标准组584 mg/min,P=.64,无显著差异。
- 12个月腮腺排泄功能适应性放疗组48% vs 标准组41%,P=.02,适应性放疗组改善。
- 两组2年总生存率均为76.9%(95%CI 64.7%-85.4%)。
核心结论
- 本随机临床试验未证明适应性放疗相比标准调强放疗能降低口干症。
- 除闪烁显像评估的腮腺排泄功能外,次要终点及生存率均无显著差异。
研究设计与样本
- 3期随机临床试验,在法国11个中心开展。
- 纳入18至75岁、接受放化疗的III-IVB期口咽鳞状细胞癌患者,2013年7月5日至2018年10月1日入组。
- 共132例患者随机(1:1)分配,适应性放疗组排除1例后,131例纳入分析:适应性放疗组66例(平均[SD]年龄60[8]岁,男性57例[86.4%]),标准调强放疗组65例(平均[SD]年龄60[8]岁,男性57例[87.7%])。
- 干预为标准化调强放疗(不重新计划)对比适应性放疗(每周系统重新计划)。
- 中位随访26.4个月(IQR 1.2-31.3个月)。
主要发现
- 12个月时石蜡刺激唾液流率平均(SD)为适应性放疗组630(450)mg/min vs 标准组584(464)mg/min(P=.64)。
- 12个月时闪烁显像评估的腮腺排泄功能平均(SD)为适应性放疗组48%(17%)vs 标准组41%(17%)(P=.02)。
- 两组2年总生存率均为76.9%(95%CI 64.7%-85.4%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Xerostomia is a major toxic effect associated with intensity-modulated radiotherapy (IMRT) for oropharyngeal cancers. OBJECTIVE: To assess whether adaptive radiotherapy (ART) improves salivary function compared with IMRT in patients with head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: This phase 3 randomized clinical trial was conducted in 11 French centers. Patients aged 18 to 75 years with stage III-IVB squamous cell oropharyngeal cancer treated with chemoradiotherapy were enrolled between July 5, 2013, and October 1, 2018. Data were analyzed from November 2021 to May 2022. INTERVENTIONS: The patients were randomly assigned (1:1) to receive standard IMRT (without replanning) or ART (systematic weekly replanning). MAIN OUTCOMES AND MEASURES: The primary end point was the frequency of xerostomia, measured by stimulating salivary flow with paraffin. Secondary end points included salivary gland excretory function measured using technetium-99m pertechnetate scintigraphy, patient-reported outcomes (Eisbruch xerostomia-specific questionnaire and the MD Anderson Symptom Inventory for Head and Neck Cancer questionnaire), early and late toxic effects, disease control, and overall and cancer-specific survival. RESULTS: A total of 132 patients were randomized, and after 1 exclusion in the ART arm, 131 were analyzed: 66 in the ART arm (mean [SD] age at inclusion, 60 [8] years; 57 [86.4%] male) and 65 in the standard IMRT arm (mean [SD] age at inclusion, 60 [8] years; 57 [87.7%] male). The median follow-up was 26.4 months (IQR, 1.2-31.3 months). The mean (SD) salivary flow (paraffin) at 12 months was 630 (450) mg/min in the ART arm and 584 (464) mg/min in the standard arm (P = .64). The mean (SD) excretory function of the parotid gland at 12 months, measured by scintigraphy, improved in the ART arm (48% [17%]) compared with the standard arm (41% [17%]) (P = .02). The 2-year-overall survival was 76.9% (95% CI, 64.7%-85.4%) in both arms. CONCLUSIONS AND RELEVANCE: This randomized clinical trial did not demonstrate a benefit of ART in decreasing xerostomia compared with standard IMRT. No significant differences were found in secondary end points except for parotid gland excretory function, as assessed by scintigraphy, or in survival rates. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01874587.
引用
- Castelli J, Thariat J, Benezery K, et al. Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37261806. doi:10.1001/jamaoncol.2023.1352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。